AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Lexaria Bioscience Corp. Director's Dealing 2022

Oct 18, 2022

34983_dirs_2022-10-18_60a17efe-51fc-4aa7-a9ba-17f0ab1f3c98.zip

Director's Dealing

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Lexaria Bioscience Corp. (LEXX)
CIK: 0001348362
Period of Report: 2022-10-14

Reporting Person: Downey Gregory (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-10-14	common shares	A	121	$2.09	Acquired	1954	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
common shares	1833	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Options	$5.04	2026-04-15	Common Shares (4000)	4000	Direct
Stock Options	$5.04	2026-04-15	Common Shares (4000)	8000	Direct
Stock Options	$5.04	2026-04-15	Common Shares (4000)	12000	Direct
Stock Options	$5.31	2026-04-26	Common Shares (5000)	17000	Direct
Stock Options	$7.08	2026-06-08	Common Shares (8000)	25000	Direct
Stock Options	$6.23	2026-09-01	Common Shares (10000)	35000	Direct
Stock Options	$2.91	2027-08-29	Common Shares (11000)	46000	Direct